{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-087903","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2025-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.300369+00:00","generated_at":"2026-05-17T06:32:26.414603+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pasithea activates two South Korean sites for PAS-004 NF1 trial; first patient dosed","bullets":["Two sites activated: Asan Medical Centre and Severance Hospital Yonsei University Health System, both now recruiting.","First patient in South Korea dosed; trial enrolling Cohort 2 (8 mg tablet) after SRC cleared Cohort 1 without modification.","Initial interim clinical data from first two cohorts expected in Q1 2026.","Phase 1/1b study of PAS-004 (macrocyclic MEK inhibitor) in adult NF1 patients with symptomatic plexiform neurofibromas.","Trial also includes sites in Australia and U.S.; Part A dose escalation (4 mg to 18 mg) identifying recommended Part B dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-087903","json":"https://secwatch.observer/filing/0001213900-25-087903.json","markdown":"https://secwatch.observer/filing/0001213900-25-087903.md","text":"https://secwatch.observer/filing/0001213900-25-087903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390025087903/0001213900-25-087903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390025087903/ea0257501-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:32:26.414603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}